CLINICAL TRIALS PROFILE FOR IOFLUPANE I-123
✉ Email this page to a colleague
All Clinical Trials for ioflupane i-123
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Institute for Neurodegenerative Disorders | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Ken Marek, MD | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
NCT01453127 ↗ | DaTSCAN Imaging in Aging and Neurodegenerative Disease | Enrolling by invitation | Mayo Clinic | Phase 4 | 2011-10-01 | The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases. |
NCT03185182 ↗ | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma | Terminated | Lund University | Phase 2 | 2017-07-14 | The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype. |
NCT03185182 ↗ | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma | Terminated | Region Skane | Phase 2 | 2017-07-14 | The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype. |
NCT03582488 ↗ | Longitudinal Imaging Biomarkers of Disease Progression in DLB | Enrolling by invitation | Kejal Kantarci | Phase 4 | 2018-06-25 | The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ioflupane i-123
Condition Name
Clinical Trial Locations for ioflupane i-123
Trials by Country
Clinical Trial Progress for ioflupane i-123
Clinical Trial Phase
Clinical Trial Sponsors for ioflupane i-123
Sponsor Name